Urgent.News

What's breaking now, across hundreds of outlets.

Finance & Markets

Tecogen director John Hatsopoulos buys $8,535 in company stock

Tecogen director John Hatsopoulos buys $8,535 in company stock

John W. Higuchi, a director at Lipocine Inc., recently made stock purchases totaling $225,225 in the company's common shares. On November 19, 2026, he bought 75,000 shares, followed by an additional 75,000 shares on November 20, 2026. The stock prices ranged from $1.4911 to $1.5119 per share during these acquisitions. Mr. Higuchi now directly owns 391,365 shares of Lipocine common stock.

The market has been experiencing a downward trend with the stock trading near its 52-week low of $1.36, resulting in a 13% decrease over the past week. Analysts at InvestingPro suggest the company may be undervalued at its current price, which could explain Mr. Higuchi's decision to invest. Lipocine's market capitalization is reported at $16.61 million, with analysts providing price targets ranging from $4 to $6 per share.

Additionally, Lipocine recently announced the commencement of its Phase 3 BLOOM trial for LPCN1154, targeting severe postpartum depression, with the first participant to be dosed in the early fourth quarter of 2026. Despite this, H.C. Wainwright has maintained a Neutral rating for Lipocine, with a price target of $4.00. The company has also updated its sales agent fee agreement with A.G.P./Alliance Global Partners, specifying a maximum fee of 3.0%, subject to potential adjustments.

Rewritten by urgent.news; may contain errors — check the original.

This story

This is one outlet's version. Read the fullest account.

Every outlet that reported this, and when →

Read the original at investing.com →

Report a problem with this story

More in Finance & Markets

More from Saturday 21 November →